UNCOVERED: 2 - Caught on Camera

What to Expect From Bristol-Myers Squibb's Next Quarterly Earnings Report

Bristol-Myers Squibb is set to release its third-quarter results by the end of this month, and analysts expect a notable double-digit drop in earnings.

Barchart · Oct 14, 2025

Bristol Myers Expands Cell Therapy Portfolio With Orbital Therapeutics Acquisition

Bristol Myers Squibb Co. (NYSE:BMY) on Friday agreed to acquire Orbital Therapeutics, a privately held biotechnology company focused on RNA medicines that reprogram the immune system in vivo.

Benzinga · Oct 10, 2025

Bristol Myers Squibb Franchise Gains Momentum With Phase 3 Results In Multiple Myeloma Patients

Bristol Myers Squibb Co. (NYSE:BMY) on Tuesday announced results from the Phase 3 EXCALIBER-RRMM study evaluating iberdomide, an investigational cereblon E3 ligase modulator (CELMoD), combined with standard therapies (daratumumab + dexamethasone) in patients with relapsed or refractory multiple myeloma (RRMM).

Benzinga · Sep 23, 2025

Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial

Bristol Myers Squibb Co. (NYSE:BMY) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating Reblozyl (luspatercept-aamt) with concomitant janus kinase inhibitor (JAKi) therapy in adult patients with myelofibrosis-associated anemia receiving red blood cell (RBC) transfusions.

Benzinga · Jul 18, 2025

Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off

The Bristol Myers Squibb Co. (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) alliance announced a new direct-to-patient option for purchasing Eliquis (apixaban) via the alliance’s patient resource, Eliquis 360 Support, on Thursday.

Benzinga · Jul 17, 2025

Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?

Bristol-Myers Squibb Co. (NYSE:BMY) is gearing up to announce its second-quarter 2025 earnings on July 31, with expectations for adjusted earnings of $1.585 per share on sales of $11.31 billion, according to data from Benzinga Pro.

Benzinga · Jul 14, 2025

What to Expect From Bristol-Myers Squibb's Q2 2025 Earnings Report

Bristol-Myers Squibb is set to announce its second-quarter results by the end of July, and analysts expect a notable drop in earnings.

Barchart · Jul 14, 2025

Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector?

Although Bristol-Myers Squibb has outshined relative to the healthcare sector over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Barchart · Jun 4, 2025

Are Wall Street Analysts Bullish on Bristol-Myers Stock?

Bristol-Myers has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Barchart · May 2, 2025

Here's What to Expect From Bristol-Myers Squibb's Next Earnings Report

Bristol-Myers Squibb is poised to announce its first-quarter results this month, and analysts predict a triple-digit growth in the company’s bottom-line figure.

Barchart · Apr 11, 2025